Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients With Thumb Osteoarthritis

● First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy ●Third study of AllocetraTM in osteoarthritis, following

GlobeNewswire08:00 ET

Enlivex Therapeutics Announces New Securities Deal

TipRanksMay 30 03:06 ET

Enlivex Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 29 16:23 ET · Announcements

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its

GlobeNewswireMay 29 16:15 ET

Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall

Enlivex Therapeutics (ENLV) said Tuesday it struck a deal to sell about 3.57 million shares and clinical milestone-linked warrants at $1.40 per share and associated warrants to a healthcare-focused in

MT NewswiresMay 28 14:41 ET

Express News | Enlivex Therapeutics Enters Agreement For Registered Direct Offering Of 3.57M Ordinary Shares And Milestone-Linked Warrants, Raising $5M Upfront And Up To $10M From Warrant Exercises

BenzingaMay 28 08:14 ET